Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans

doi:10.1016/j.jaci.2018.01.039

Journal of Allergy and Clinical Immunology

Volume 142, Issue 4, October 2018, Pages 1285-1296

, , , , , , , , , , , , , , , , , , , …

https://doi.org/10.1016/j.jaci.2018.01.039 Get rights and content

Under a Creative Commons license

open access

Background

The genetic cause of primary immunodeficiency disease (PID) carries prognostic information.

Objective

We conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource–Rare Diseases cohort.

Methods

In the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor κB subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses.

Results

Both sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21^low B-cell population. Combined with identification of the disease-causing variant, this distinguishes between healthy subjects, asymptomatic carriers, and clinically affected cases.

Conclusion

We show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.

Graphical abstract

Key words

B cells

common variable immunodeficiency

nuclear factor κB1

Abbreviations used

CFSE

Carboxyfluorescein succinimidyl ester

CVID

Common variable immunodeficiency

LOF

Loss-of-function

NF-κB

Nuclear factor κB

NFKB1

Nuclear factor κB subunit 1

NIHRBR-RD

NIHR BioResource–Rare Diseases

PID

Primary immunodeficiency disease

PML

Progressive multifocal leukoencephalopathy

RHD

Rel homology domain

VEP

Variant effect predictor

Cited by (0)

: Supported by The National Institute for Health Research England (grant no. RG65966) and the Center of Immunodeficiencies Amsterdam (CIDA). J.E.T. is supported by an MRC Clinician Scientist Fellowship (MR/L006197/1). A.J.T. is supported by both the Wellcome Trust (104807/Z/14/Z) and the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.

: Disclosure of potential conflict of interest: S. O. Burns has received grants from HEFCE, University College London, the National Institute of Health Research (NIHR), UCLH III BRC, and GOSH/ICH BRC and has received personal fees from CSL Behring, Immunodeficiency Canada/IAACI, CSL Behring, Baxalta, and Octagam. A. Chandra has received grants from the Wellcome Trust and GlaxoSmithKline. H. J. Longhurst has received personal fees from BioTest, CSL Behring, and Baxalta; has received grants from CSL Behring; has received nonfinancial support from BioTest and CSL Behring; and has research collaborations with CSL Behring and GlaxoSmithKline. E. Oksenhendler has received personal fees from CSL Behring and MSD. A. J. Thrasher has received personal fees from Orchard Therapeutics, Rocket Pharmaceuticals, and Torus Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest.

^∗: These authors contributed equally to this work.

^‡: These authors contributed equally to this work.